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No baclofen for alcohol use disorders even more when liver disease is serious! 
 
 
Alain Braillon (1), Florian Naudet (2) 
 
(1) Alcohol Treatment Unit, University Hospital, 8000 Amiens, France. braillon.alain@gmail.com  
(2) Université de Rennes, Centre Hospitalier Universitaire de Rennes, Inserm, Centre d'Investigation 
Clinique, 35000 Rennes, France.  
 
AB and FN serve as unpaid experts for several taskforces for the French national agency of medicine 
and health product safety (Agence Nationale de Sécurité du Médicament et des Produits de Santé), 
none of which were related to the topic. No other competing interests. 
 
No funding. 
 
Keywords: Baclofen, alcohol use disorders, liver disease, abstinence, off-label use. 
 
Caputo and colleagues wrongly promoted baclofen for patients with end-stage alcoholic liver 
disease.(1)  
First, there is no reason to use it. A recent Cochrane review found a negative benefit harm:ratio of 
baclofen. This precludes any off-label use. Preliminary hypotheses from two short series from the 
same team have been ruled out by a recent robust trial in 320 patients which failed to demonstrate an 
effect of baclofen in the maintenance of abstinence.(2) Concerning use of the baclofen for only 
decreasing the amount drunk (so-called “harm reduction”), there is no evidence on relevant clinical 
outcomes yet.(3) The largest trial, NCT01604330, in this indication is problematic: data collection 
ended in 2015 but no publication yet, only a meeting presentation with no benefit but a two fold 
increase in mortality.(4) We attempted to obtain clinical study reports, statistical analysis plan, and 
individual patient data as part of the Restoring Invisible and Abandoned Trials initiative (2) The 
sponsor, the drug company, the French drug agency declined our requests. 
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Second, there are major reasons to avoid it. A French pharmaco-epidemiological study in 165,334 
patients treated for alcohol use disorders between 2009 and 2015 showed a dose related increase 
mortality with off-label baclofen (HR = 1.4 for 30-75 mg/day, 1.5 for 75-180 mg/day; 2.3 over 
180mg/day) vs acamprosate and naltrexone.(5) Australia's largest Poisons Information Centre 
confirmed this increase in serious adverse effects with off-label use for alcohol use disorders.  
E in EBM means evidence not expectations. Moreover, could it be wise to only aim for harm 
reduction in a patient with end-stage alcoholic liver disease? Abstinence is the only rational goal. 
Who would advise a patient recovering from stroke to try to decrease it smoking addiction by one or 
two cigarettes a day? Last, off-label drug use is too frequently not supported by sound scientific 
evidence, hinders the development therapeutic innovation, is costly to the healthcare system, and 
exposes patients to the unnecessary risk of serious adverse events for an all too often uncertain 
benefit. 
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